ArticleAnnals of hematology2025
Follicular lymphoma or diffuse large B-cell lymphoma: a population based analysis of epidemiological and health economic aspects in Germany.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond medical costs: a call for integrating psychosocial support into lymphoma care policy.Annals of hematology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Contemporary information on epidemiology, healthcare resource utilization (HCRU), costs and clinical outcomes in routine care is essential for value-based decision-making. However, such information remains limited for follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) in Germany. This study addresses these gaps. This retrospective cross-sectional cost-of-illness study analyzed anonymized statutory health insurance claims data (2015-2020). FL Grade I-IIIa (ICD-10: C82.0-C82.3), DLBCL (ICD-10: C83.3) patients were identified via inpatient or outpatient ICD coding. Elixhauser and Charlson Comorbidity Indices were used to describe the general comorbidity burden. FL prevalence increased from 26 to 32 per 100,000 insured persons (n = 837 to 1,028), DLBCL prevalence rose from 37 to 45 per 100,000 (n = 1,205 to 1,437). Mean age (FL: 67.0 ± 13; DLBCL: 68.6 ± 13.6) and sex distribution (FL: 50% female; DLBCL: 44% female) remained stable 2015-2020. Mean Charlson Comorbidity Index 4.1 ± 2.4 (FL), 4.8 ± 2.7 (DLBCL), mean Elixhauser 5.2 ± 3.0 (FL), 6.1 ± 3.3 (DLBCL). Hospitalization rates: 64% of FL patients (2.0 ± 2.3 admissions, 21 ± 44.7 days/year); 78% of DLBCL patients (2.9 ± 3.1 admissions, 29 ± 47.5 days/year). Mean annual costs per patient in third-party payers perspective were €15,258 (FL), €23,455 (DLBCL). Post-SCT 12-month costs were €46,270 (FL), €56,558 (DLBCL) for autologous-SCT, and €161,662 for allogeneic-SCT (DLBCL only). Rising prevalence calls for ongoing real-world assessment of HCRU and costs. This study supplements limited evidence, highlighting significant economic impact. While health insurance data offer valuable insights, their lack of clinical details necessitates integration with other data sources. Several initiatives are building data spaces to enhance evidence generation; meanwhile, analyses based on single data sources remain valuable to inform practice and policy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.